Download PDF
Homeopathy 2012; 101(04): 217-223
DOI: 10.1016/j.homp.2012.08.005
Original Paper
Copyright © The Faculty of Homeopathy 2012

Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial

A.K. Hati
1   Dr. Abhin Chandra Homoeopathic Medical College & Hospital, Unit-III, Bhubaneswar, 751 001 Odisha, India
,
B. Paital   a
2   Department of Zoology and Biotechnology, Utkal University, Bhubaneswar 751 004, India
,
K.N. Naik
1   Dr. Abhin Chandra Homoeopathic Medical College & Hospital, Unit-III, Bhubaneswar, 751 001 Odisha, India
,
A.K. Mishra
1   Dr. Abhin Chandra Homoeopathic Medical College & Hospital, Unit-III, Bhubaneswar, 751 001 Odisha, India
,
G.B.N. Chainy   b
2   Department of Zoology and Biotechnology, Utkal University, Bhubaneswar 751 004, India
,
L.K. Nanda
1   Dr. Abhin Chandra Homoeopathic Medical College & Hospital, Unit-III, Bhubaneswar, 751 001 Odisha, India
› Author Affiliations
Subject Editor:
Further Information

Publication History

Received16 February 2011
revised18 July 2012

accepted06 August 2012

Publication Date:
02 January 2018 (online)

Also available at
    Permissions and Reprints

Background: Benign Prostatic Hypertrophy (BPH) is common in older men. This study compared homeopathic treatment strategies using constitutional medicines (CM) or organopathic medicines (OM) alone or in combination (BCOM) in patients suffering from BPH.

Methods: 220 men aged 30–90 years were recruited in Odisha, India. Patients presenting symptoms of prostatism, with or without evidence of bladder outflow obstruction were included in the study. Patients with serum prostate specific antigen (PSA)> 4 nmol/mL, malignancy, complete urine retention, stone formation and gross bilateral hydronephrosis were excluded. Patients were sequentially allocated to OM, CM or BCOM. The main outcome measure was the International Prostate Symptom Score (IPSS).

Results: 73, 70 and 77 patients respectively were sequentially allocated to OM, CM or BCOM. 180 patients (60 per group) completed treatment and were included in the final analysis. Overall 85% of patients showed improvement of subjective symptoms such as frequency, urgency, hesitancy, intermittent flow, unsatisfactory urination, feeble stream, diminution of residual urine volume but there was no reduction in prostate size. Treatment response was highest with BCOM (38.24%) compared to OM (31.62%) and CM (30.15%). Effect sizes were highest for the decrease in IPSS, residual urine volume and urinary flow rate.

Keywords

Homeopathy - Constitutional - Organopathic - Combined benign prostatic hypertrophy - Effectiveness - Treatment

a Present address: Biochemical Adaptation Lab., Department of Zoology, Banaras Hindu University, Varanasi 221005, UP, India. Tel.: +91 542 6702523; fax: +91 542 2368174.


b Present address: Imgenex India Pvt. Ltd., E-5, Infocity, Bhubaneswar 751024, India. Tel.: +91 674 3296544; fax: +91 674 2741046.


 

  • References

  • 1 Cristoni A., Di Pierro F., Bombardelli E. Botanical derivatives for the prostate. Fitoterapia 2000; 1: S21-S28.
    PubMedSearch in Google Scholar
  • 2 Caprino L. Drugs for the treatment of benign prostatic hypertrophy. Minerva Urol Nefrol 2000; 52 (02) 87-92.
    PubMedSearch in Google Scholar
  • 3 Semino A.M., Lozano O.J.L., Garcia C.E., Tejeda B.E., Romero R.F. Symptomatic treatment of benign hypertrophy of the prostate. Comparative study of prazosin and serenoa repens . Arch Esp Urol 1992; 45 (03) 211-213.
    PubMedSearch in Google Scholar
  • 4 Paubert-Braquet M., Richardson F.O., Servent-Saez N. et al. Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat. Pharm Res 1996; 34 (03/04) 171-179.
    CrossrefPubMedSearch in Google Scholar
  • 5 Paubert-Braquet M., Mencia H.J.M., Cousse H., Braquet P. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids 1997; 57 (03) 299-304.
    CrossrefPubMedSearch in Google Scholar
  • 6 Nix J.W., Carson C.C. Medical management of benign prostatic hypertrophy. Can J Urol 2007; 1: 53-57.
    PubMedSearch in Google Scholar
  • 7 Stamatiou K. Management of benign prostatic hypertrophy-related urinary retention: current trends and perspectives. Urol J 2009; 6 (04) 237-244.
    PubMedSearch in Google Scholar
  • 8 Mantovani F. Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies. Minerva Urol Nefrol 2010; 62 (04) 335-340.
    PubMedSearch in Google Scholar
  • 9 Murphy R.N.D. Homoeopathic medical repertory. New Delhi, India: B. Jain Publishers (P) Ltd; 1998. p. 1246.
    Search in Google Scholar
  • 10 Schroyens F. Synthesis repertorium syntheticum. New Delhi, India: B. Jain Publishers (P) Ltd; 2005. p. 970.
    Search in Google Scholar
  • 11 Knerr C.B. Repertory of Hering's guiding symptoms of our Materia Medica. New Delhi, India: B. Jain Publishers (P) Ltd; 2002. p. 625.
    Search in Google Scholar
  • 12 Kent J.T. Kent's repertory of the homoeopathic Material Medica. New Delhi, India: B. Jain Publishers (P) Ltd; 2004. p. 625.
    Search in Google Scholar
  • 13 Boericke W. Organon of Medicine. New Delhi, India: B. Jain Publishers (P) Ltd; 2004. p. 220.
    Search in Google Scholar
  • 14 Barry M.J., Fowler Jr. F.J., O'Leary M.P. et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148 (05) 1549-1557.
    CrossrefPubMedSearch in Google Scholar